Author: Ken Dropiewski

ABK Biomedical Raises US$35M in Series D Financing

inancing  supports ongoing clinical operations, development, and commercialization preparation HALIFAX, NS, Oct. 14, 2025 /PRNewswire/ – ABK Biomedical, Inc., an innovative medical device company dedicated to the research, development, and commercialization of advanced imageable embolic medical devices, today announced an oversubscribed US$35 million Series D financing. The round was led by new investor, J.P. Morgan Life […]

Medtronic Endurant™ stent graft system first and only to receive FDA labeling approval to remove rAAA treatment warning

With this labeling approval, Medtronic continues to lead the way in advancing aortic care with clinical evidence for the treatment of ruptured abdominal aortic aneurysms (rAAA). Medtronic plc, a global leader in healthcare technology, today announced it has received U.S. Food and Drug Administration (FDA) labeling approval1 for the Medtronic Endurant™ […]

Lumina 3D by RapidAI Named to TIME’s List of the Best Inventions of 2025

SAN MATEO, Calif.–(BUSINESS WIRE)–RapidAI, the pioneer of deep clinical AI and the global leader in image-based decision support and workflow efficiencies, today announced that its Lumina 3D™ built on the Rapid Enterprise™ Platform has been named to TIME’s List of the Best Inventions of 2025, honoring 300 extraordinary innovations changing the […]

Adagio Medical Unveils Preliminary Acute Results from FULCRUM-VT U.S. Pivotal Study in Late Breaking Session at VT Symposium

97% Acute Effectiveness and Favorable Safety Results from Proprietary ULTC for Ventricular Tachycardia LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced preliminary acute (within 7 days) safety and efficacy results […]

Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse™ Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting

uccessfully treated atrial fibrillation (AF) in initial 30 patients with the nPulse™ Cardiac Surgical System HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced late-breaking clinical study results from the nPulse™ […]

Shape Memory Medical Announces Approvals for the IMPEDE Embolization Plug Product Family in Singapore and Malaysia

SAN JOSE, Calif.–(BUSINESS WIRE)–Shape Memory Medical Inc., the innovator of the only commercially available volume-expanding shape memory polymer for endovascular embolization applications, announced today that it has received approvals from both Singapore’s Health Science Authority (HSA) and Malaysia’s Medical Device Authority (MDA) to market the IMPEDE Embolization Plug, the IMPEDE-FX […]

Viz.ai Launches Viz ACS™ to Accelerate Treatment for Heart Attack and Reduce Unnecessary Activations

SAN FRANCISCO–(BUSINESS WIRE)–Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the launch of Viz ACS, a new solution in the Viz Cardio™ Suite. Designed to unite the acute coronary syndrome (ACS) care team on a single platform, Viz ACS provides Emergency Department (ED) physicians and […]

Vasa Therapeutics Receives FDA IND Clearance to Advance Novel Small Molecule VS-041 for the Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)

Phase 1c Clinical Trial to Begin Immediately ENCINITAS, Calif. and WROCLAW, Poland, Oct. 13, 2025 /PRNewswire/ — Vasa Therapeutics, (“Vasa”), a private, clinical stage biotechnology company developing novel therapies for cardiovascular and metabolic aging, today announced that the U.S….

Stereotaxis and CardioFocus Collaborate to Advance Robotic Pulsed Field Ablation for Cardiac Arrhythmias

ST. LOUIS and MARLBOROUGH, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, and CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for cardiac arrhythmias, today announced they have entered into a Collaboration Agreement to advance robotic Pulsed Field Ablation (PFA) technology towards commercialization.